Gilead Sciences, Inc. (GILD): Rumor News

GILD – The Evening Standard discusses market rumors that Gilead & GlaxoSmithKlein may be eyeing United Therapeutics.


Key Facts Surrounding This News Item


  • GILD had a POWR Rating of B (Buy) coming into today.
  • GILD was -0.71% below its 10-Day Moving Average coming into today.
  • GILD was 2.10% above its 20-Day Moving Average coming into today.
  • GILD was 7.60% above its 50-Day Moving Average coming into today.
  • GILD was 9.75% above its 100-Day Moving Average coming into today.
  • GILD was 6.91% above its 200-Day Moving Average coming into today.
  • GILD had returned +5.50% year-to-date leading up to today’s news, versus a +11.50% return from the benchmark S&P 500 during the same period.

More Info About Gilead Sciences, Inc. (GILD)


Gilead Sciences is a biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs. The Company’s primary areas of focus include HIV/AIDS, liver disease and serious cardiovascular and respiratory conditions. View our full GILD ticker page with ratings, news, and more.

Try StockNews.com Premium Today!


Get access to our daily newsletters, Best Stocks List, POWR Ratings, and much more!
Free for 14 days -- no credit card required!

Sign Up Now

GILD at a Glance

GILD Current POWR Rating™
Overall POWR Rating™
GILD Current Price $80.91 1.90%
More GILD Ratings, Data, and News

GILD Price Reaction

The day of this event (Aug. 4, 2017)
GILD Closing Price$72.21 1.63%
GILD Volume15,157,272
55.02% from avg
Leading up to this event
GILD 1-mo returnN/A%
After this event
GILD 1-day return1.27%
GILD 3-day return0.64%
GILD 5-day return2.72%

GILD Price Chart



More Gilead Sciences, Inc. (GILD) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All GILD News
Page generated in 1.2844 seconds.